News

George Thompson, MD, explains a rise in Valley fever cases in CA, with concerns about increased virulence, ICU admissions, and the impact of droughts and wildfires on fungal spread.

Oral omadacyline or linezolid was equally efficacious to intravenous dosing for acute bacterial skin infections, and associated with less cost and risks.

David W Denning, FRCP, FRCPath, FMedSci, outlines the "95-95 by 2025" initiative to diagnose and treat 95% of serious fungal infections globally by 2025, focused on improving access in underserved regions.

As a new administration is taking hold, Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, discusses the last administration’s approach to the 2026 Notice of Benefit and Payment Parameters rule and its effects on patient cost-sharing.

Sasirekha Ramani, PhD, discusses the potential of 2′FL as a treatment for norovirus and what more research could reveal.

In the third installment of our series on preparedness, Gavin Harris, MD, discusses the principles and challenges of biorisk management, focusing on infectious disease threats and containment strategies.

Caryn Fenner and Petro Terblanche outline Afrigen's clinical trial plans, local partnerships, and vaccine pipeline.

In the second interview segment with George Thompson, MD, he provides feedback on patient profiles and prescribing practices for the antifungal.

Caryn Fenner and Petro Terblanche explain how CEPI’s $6.2 million grant will advance Afrigen’s mRNA vaccine for Rift Valley fever through preclinical and Phase I trials in Africa.

The COVID-19 pandemic underscored the urgent need for global pandemic preparedness. The World Health Organization (WHO) is leading efforts to establish a global treaty to address future pandemics, with findings expected in 2025. Central to this preparedness is immunomics, a field leveraging advanced genomics technologies to study the immune system at unprecedented levels of detail.

Roche's cobas liat molecular tests for chlamydia, gonorrhea, and Mycoplasma genitalium provide fast, accurate diagnoses in under 20 minutes.

The federal government is working on measures to mitigate the potential impact including looking at vaccines, therapies, and other strategies. Robert Hopkins, Jr, MD, medical director, National Foundation for Infectious Diseases (NFID), provides some insights on our preparation now and lessons learned from the pandemic.

Review finds Long COVID patients experience executive function impairments impacting tasks like shifting, inhibition, and working memory, affecting daily activities.

George Thompson, MD, offers some insights on 2 studies looking at these antifungals in patients with candidemia and invasive candidiasis.

This investment will support the development of a rapid diagnostic platform for neonatal sepsis care by identifying infections and resistance markers within hours.

NACCHO’s CEO Lori Tremmel Freeman discusses efforts and emphasizes the need for federal support and coordination.

Promptly vaccinating the "ring" of contacts and contacts-of-contacts along with standard infection control measures interrupted Ebola transmission in the DRC.

Significant value can be offered through the incorporation of stewardship concepts into infection guidelines, but we must also address the risk and challenges it may impose on health care systems.

Following up on the goal, set in 2015, to diagnose 95% and treat 95% of serious fungal infections by year-end 2025.

Here is a novel use of ceftaroline to treat methicillin-resistant Staphylococcus epidermidis ventriculitis in a preterm infant with a ventriculosubgaleal shunt.

Growing threat of beta-lactamase resistance genes across human and animal health, efforts to reduce HIV disparities for Black women, the "skip phenomenon" in S lugdunensis endocarditis, and more.

CEO Lori Tremmel Freeman discusses NACCHO's capacity-building programs and strategies to strengthen local health departments in addressing evolving public health threats.

Robert H. Hopkins, Jr, MD, medical director, National Foundation for Infectious Diseases (NFID) provides an update on incidence rates and virus patterns across different regions of the US.

Mary Rochelle Smith, MD, Julie J Lee, MD, and Amy Chang, MD, PharmD, share expert strategies for implementing effective clinical decision support tools in practice.

Study shows 2′-fucosyllactose, a sugar in human milk, could reduce norovirus replication, offering hope for new treatments amid rising cases.

The federal agency is asking hospitalists and labs to accelerate this process in order to know if they are dealing with avian influenza.

In persons living with HIV and diabetes, the management of diabetes is lagging behind the evidence. Despite SGLT-2 inhibitors demonstrating robust clinical data in the general population, they are grossly underused in persons with HIV and diabetes.

Patrick D Crowley, DO explains the impact of the "skip phenomenon" in Staphylococcus lugdunensis infective endocarditis, linking it to longer hospital stays and higher mortality rates.

There are high infection rates in this population, but limited opportunities to bring about awareness and education. However, a newer program sponsored by ViiV Healthcare looks to engage these women and bring about a better understanding behind transmission and care.

A new treatment of albendazole and ivermectin shows higher efficacy against Trichuris trichiura and hookworm infections, offering a new treatment approach for soil-transmitted worms.